Califf admits Aduhelm decision impacted experts’ trust in FDA; ARPA-H will be part of NIH — with a twist

FDA Commissioner Robert Califf admitted Thursday that the agency's controversial approval of Aduhelm has diminished its standing with experts. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Califf admits the FDA's Alzheimer's drug decision impacted experts' trust in the agency By Nicholas Florko Hechler Photographers for STAT "It's pretty clear that the controversy around [Aduhelm] has temporarily impacted the trust in the FDA" by experts, the FDA leader said. Read More STAT+: Biden's high-stakes biomedical science agency ARPA-H will be part of the NIH — but there's a twist By Lev Facher Lydia Polimeni/National Institutes of Health The Biden administration’s new research agency, ARPA-H, will exist as part of the National Institutes of Health — but with a twist. Read More Even as medicine becomes more diverse, main authors in elite journals remain mostly white and male By Usha Lee McFarling Adobe Women and people of color rarely served as lead or senior authors of research articles published in two leading medical journals. Read More Sponsor content by STAT Events A conversation with the STAT Madness crowd favorite Each year, universities and research institutions across the country compete in STAT Madness, a bracket-style tournament, in order to be recognized as having produced the top biomedical innovation or discovery of the year. Register for a virtual event on April 20 to hear researchers from the winning team discuss their work. STAT+: With pharma still struggling in Alzheimer's, health tech companies want a swing By Katie Palmer Adobe The pharmaceutical industry is still struggling to tackle Alzheimer's disease. Now, health tech companies are now trying their hand. Read More In the wake of big patent decision, it's business as usual for CRISPR therapy developers By Megan Molteni Hechler Photographers for STAT "I think it's really a topic for people interested in IP law," the chief operating officer of CRISPR Therapeutics said of the patent fights. Read More STAT+: Vertex's non-opioid painkiller meets goals in mid-stage studies By Damian Garde Bill Sikes/AP Vertex now plans to advance VX-548 into pivotal studies in the second half of this year, pending permission from the FDA. Read More STAT+: 5 technology trends drawing investment as health care moves into the home By Mohana Ravindranath Adobe Entrepreneurs and investors are cashing in on what analysts see as an inevitable shift in health care away from hospitals and into homes. Read More Pandemic took a toll on teen mental health, CDC report says By Mike Stobbe — Associated Press Charlie Riedel/AP Experts have warned that pandemic isolation from school closures and lack of social gatherings has taken a toll on youth mental health. Read More Thursday, March 31, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser